Treatment of fusiform ascending aortic aneurysms: A comparative study with 2 options  by Zhang, Hao et al.
A
C
D
Acquired Cardiovascular Disease Zhang et alTreatment of fusiform ascending aortic aneurysms: A comparative
study with 2 optionsHao Zhang, MD, Fanglin Lu, MD, Dan Qu, MD, Lin Han, MD, Jibin Xu, MD, Guangyu Ji, MD, and
Zhiyun Xu, MDFrom th
Medi
Disclosu
Receive
for pu
Address
Hosp
(E-ma
0022-52
Copyrig
doi:10.1
738Objective: Ascending aortic replacement and reinforced reduction aortoplasty are 2 optional procedures for the
treatment of fusiform ascending aneurysms. This study was designed to compare the early and late results of these
2 options.
Methods: Between January 2000 and January 2008, 71 patients with fusiform ascending aortic aneurysms and
aortic valve disease underwent reinforced reduction aortoplasty associated with aortic valve replacement (RRA
group, n ¼ 32) or ascending aortic replacement combined with aortic valve replacement (AAR group, n ¼ 39).
Patients requiring other concomitant cardiac procedures were excluded. Perioperative events and late results were
compared.
Results: The variables of the 2 groups were similar, except age and preoperative diameter of the ascending aorta.
Despite the nearly identical perioperative morbidity in the 2 groups, mean cardiopulmonary bypass time and aor-
tic crossclamping time were shorter in the RRA group. The follow-up period was between 1 and 8 years (mean, 3
years and 4 months). The 5-year survival rate was 90.7% 6.4% versus 87.0% 6.3%, respectively. Although
there was a significant increase in aortic sinus diameters in the AAR group, all aortic sinus diameters were within
the acceptable range. There was no increase in proximal aortic arch diameters in the 2 groups.
Conclusions: For the treatment of fusiform ascending aortic aneurysms, both procedures can result in favorable
and comparable late results in appropriate patients. Furthermore, reinforced reduction aortoplasty should be en-
couraged more because of its significant operative simplicity and safety if only the quality of the aortic wall is
acceptable. (J Thorac Cardiovasc Surg 2011;141:738-43)In modern cardiovascular surgery it remains controversial
whether reinforced reduction aortoplasty (RRA) or ascend-
ing aortic replacement (AAR) should be applied to patients
with fusiform ascending aortic aneurysms.1,2
Reductionaortoplasty isgenerallyconsideredaconservative
method2 because the native endothelium-lined aorta is
preserved and surgical invasion is relatively reduced.3-5
However, risk of redilatation, dissection, or rupture of the
ascending aorta has been reported in long-term follow-up.2,6
In consideration of this, it has been strongly recommended
that external reinforcement with a Dacron vascular prosthesis
should be applied for all reduction aortoplasty procedures.1
In contrast, AAR has been considered a radical procedure
that demonstrates satisfactory long-term results,7,8 although
resulting in more surgical risks in the early postoperative
period,7,9 and might play a role as a risk factor for the
development of aortic root dilatation10 by increasing walle Division of Cardiothoracic Surgery, Changhai Hospital, Second Military
cal University, Shanghai, China.
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The Journal of Thoracic and Cardiovascular Surgtension in the residual aorta.11Basedonconflicting standpoints
in the literature, the controversy of repair or replacement per-
sists to date. To address this confusing clinical issue, we
designed this study to compare the perioperative events and
late results of RRA and AAR.
MATERIALS AND METHODS
We retrospectively reviewed the database for the Division of Cardiotho-
racic Surgery at the Second Military Medical University and identified all
patients undergoing either aortic valve replacement (AVR) with RRA or
AVR with AAR between January 2000 and January 2008. The patients
who underwent other concomitant cardiac procedures were therefore ex-
cluded from this study. None of the patients had Marfan syndrome or aortic
dissection. The aortic aneurysm was fusiform in all patients without aortic
root involvement.
A total of 71 patients were available for the final analysis. Preoperative
demographic characteristics, operative variables, and postoperative and
follow-up results were retrieved from the database. In 32 patients (the
RRA group) AVR was performed with RRA. In the remaining 39 patients
(the AAR group), AVR was performed with concomitant AAR.
Surgical Technique
Surgical procedures were performed by the members of the Division of
Cardiothoracic Surgery at the Second Military Medical University. The
choice between 2 procedures was made preoperatively according to inte-
grated evaluation of the following factors: quality of the ascending aortic
wall, size of the aneurysm, and operative risk, as well as age.
All procedures were carried out under median sternotomy, cardiopulmo-
nary bypass, andmoderate hypothermia,with cardioplegic arrest formyocar-
dial protection. The aortic cannula was placed in the proximal aortic arch orery c March 2011
TABLE 1. Preoperative and intraoperative demographics
Variable
RRA group
(n ¼ 32)
AAR group
(n ¼ 39)
P
value
Age (y) 56.7  9.2 51.3  11.6 .04
Male sex 17 (53%) 29 (74%) .06
LV ejection fraction (%) 59.9  6.1 61.2  6.5 .37
NYHA class III or IV 6 (16%) 7 (10%) .72
Diabetes mellitus 2 (6%) 2 (5%) .84
Hypertension 6 (19%) 5 (13%) .49
Bicuspid aortic valve 13 (41%) 21 (54%) .27
Diameter of ascending aorta (mm) 47.9  4.0 54.3  5.3 <.001
Diameter of aortic sinuses (mm) 30.4  0.9 30.6  1.0 .53
Diameter of proximal
aortic arch (mm)
28.9  1.0 29.3  1.1 .20
RRA, Reinforced reduction aortoplasty; AAR, ascending aortic replacement; LV, left
ventricular; NYHA, New York Heart Association.
TABLE 2. Operative and postoperative details
RRA group AAR group P
Abbreviations and Acronyms
AAR ¼ ascending aortic replacement
AVR ¼ aortic valve replacement
BAV ¼ bicuspid aortic valve
RRA ¼ reinforced reduction aortoplasty
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cision was made in the ascending aorta after crossclamping through a longi-
tudinal aortotomy beginning below the aortic clamp and extending into the
noncoronary sinus in the patients undergoing RRA or through a transverse
incision above the sinuses in the patients undergoing AAR. After cardiople-
gic arrest was achieved, the aortic valve was excised and replaced with a me-
chanical prosthesis or bioprosthesis. The aortoplasty was performed by
means of removal of an elliptical portion of the dilated aortic wall along
the aortotomy incision, as described by Robicsek and Thubrikar.3 The pa-
tient was weaned from cardiopulmonary bypass after the aortotomy was
closed with 4–0 Prolene double-running sutures. A Dacron tube graft with
a diameter of approximately 28 to 30mmforwrapping of the ascending aorta
was cut longitudinally, and 2 pieces of the prosthesis were excised from the
ends of the graft. The reduced aorta was wrapped with the formed prosthesis
thereafter. Thewrapwas stabilized by both distal anchoring to thewall of the
aortic arch and proximal anchoring to the suture ring of the valve prosthesis
and the aortic wall before closure with a running nonabsorbable suture.
AAR was performed with an approximately 28- to 30-mm Dacron tube
graft replacing the dilated ascending aorta above the level of the sinuses.
Follow-up
Follow-up information was obtained by means of retrospective review of
medical records or by means of postal questionnaire and telephone inter-
views. The diameters of the aorta were all retrieved from computed tomo-
graphic scans preoperatively, postoperatively, and during the follow-up
period. The measurement was made at the level of bifurcation of the pulmo-
nary artery, aortic sinuses, and proximal aortic arch, respectively.
Statistical Methods
Categorical variables are expressed as percentages, and continuous vari-
ables are expressed as means  standard deviations throughout the article.
Comparison of categorical variables was performed with the c2 test, and
continuous variables were analyzed with the Student’s t test. Comparisons
of aortic diameters were analyzed by means of analysis of variance for re-
peated measures, and Bonferroni’s method was used for multiple compari-
sons. Long-term survival was analyzed with the methods of Kaplan–Meier.
Comparisons with groups were made by using the log-rank test. Cox regres-
sion was used to identify factors associated with late death.
Variable (n ¼ 32) (n ¼ 39) value
CBP time (min) 82  13 104  16 <.001
Aortic crossclamp time (min) 43  9 67  15 .001
Total pRBCs (unit) 3.5  1.7 4.8  2.1 .01
IABP support 0 0 
Mortality 0 0 
Re-exploration for bleeding 2 (6.2%) 3 (7.7%) .81
Prolonged ventilation 1 (3.1%) 0 .26
Stroke 1 (3.1%) 1 (2.6%) .89RESULTS
Preoperative Demographics
The preoperative demographics of the study groups are
shown inTable 1. Patients undergoingRRAwere significantly
older than those undergoing AAR, who were more likely to
have larger ascending aortic diameters. There were no signif-
icant differences in the other variables between the 2 groups.
Renal dysfunction 2 (6.2%) 2 (5.1%) .84
ICU stay (d) 2.2  1.5 3.0  1.9 .05
Total in-hospital stay (d) 14.4  3.8 17.2  4.4 .01
RRA, Reinforced reduction aortoplasty; AAR, ascending aortic replacement; CPB, car-
diopulmonary bypass; pRBCs, packed red blood cells; IABP, intra-aortic balloon
pump.Operative and Postoperative Details
The operative and postoperative details for the 2 groups
are listed in Table 2. There were no operative deaths in
either group. The mean cardiopulmonary bypass and aorticThe Journal of Thoracic and Cacrossclamping times in the RRA group were shorter than
those in the AAR group (82  14 vs 113  19 minutes
[P< .001] and 42  10 vs 71  20 minutes [P< .001], re-
spectively). Less red blood cells were used for patients in the
RRA group than in the AAR group (3.5  1.7 vs 4.8  2.1
units, P ¼ .01). The total in-hospital stay of the RRA group
was significantly shorter than that of the AAR group (14.4
3.8 vs 17.2 4.4 days, P¼ .01). Intra-aortic balloon support
was not used in all patients. There were no statistically sig-
nificant differences in rates of perioperative re-exploration
for bleeding, respiratory insufficiency, stroke, or renal dys-
function between the groups (P> .05).
Late Results
The follow-up period was between 1 and 8 years (mean, 3
years and 4 months). The follow-up was complete in all pa-
tients. Three patients in the RRA group and 5 patients in the
AAR group died during late follow-up. A total of 63 patients
were alive at the time of the last follow-up examination.rdiovascular Surgery c Volume 141, Number 3 739
FIGURE 1. Overall survival of patients in the whole series (Kaplan–Meier curve 95% confidence interval). Numbers of patients at risk at each time point
are noted. RRA, Reinforced reduction aortoplasty; AAR, ascending aortic replacement.
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4.5% at 5 years (Figure 1). The 5-year survival rate was
90.7%  6.4% in the RRA group and 87.0%  6.3% in
the AAR group (Figure 2). There was no difference in the
survival of the patients in the 2 groups (P ¼ .59).
There were 2 cardiac-related deaths during follow-up,
with myocardial infarction in 1 patient of the RRA group
and sudden death in 1 patient of the AAR group. Six noncar-
diac deaths occurred during follow-up. Two patients died of
cancer and traffic accidents in the RRA group. Four deaths in
the AAR group were attributed to cancer, renal failure, cere-
bral bleeding, and pneumonia, respectively.
There were no reoperations on the aorta or aortic valve in
all patients during follow-up.
Only age was found to be a significant predictor in deter-
mination of late death in each group. The type of aortic pro-
cedure was not a significant predictor of late death in the
whole cohort (P¼ .593). Other factors, such as sex, left ven-
tricular ejection fraction, bicuspid aortic valve (BAV), and
preoperative diameters of the ascending aorta were notFIGURE 2. Survival of patients in the reinforced reduction aortoplasty (RRA) a
no difference in survival between groups. Numbers of patients at risk at each tim
740 The Journal of Thoracic and Cardiovascular Surgsignificant predictors in either group. Table 3 outlines vari-
ables that were evaluated for their effect on late death by us-
ing Cox regression.
Variation of Aortic Diameters
Both procedures resulted in a significant reduction in as-
cending aortic diameter (RRA group: 47.9  4.0 vs 27.3 
0.7 mm, P ¼ .000; AAR group: 54.3  5.3 vs 29.5  0.4
mm, P ¼ .000).
The mean diameters of the aortic sinuses and proximal
aortic arch in all patients are shown in Figure 3 for each group
as a function of time. Thirty-nine patients (18 in the RRA
group and 21 in the AAR group) who accumulated at least
60 months of follow-up were further analyzed for assessing
late redilatation in the aorta. In these patients there was no
difference in the diameters of the aortic sinuses between
the postoperative and late follow-up periods in the RRA
group (30.4  0.7 vs 30.8  1.1 mm, P ¼ .097). The diam-
eters of the sinuses increased significantly in the AAR group
during follow-up (postoperatively: 30.6  0.8 mm vs latend ascending aortic replacement (AAR) groups during follow-up. There was
e point are given.
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TABLE 3. Cox regression of variables related to late death
Variable
P value
RRA group AAR group
Age .038 .006
Sex .937 .896
EF .393 .112
Bicuspid valve .684 .506
Preoperative ascending
aorta diameter
.149 .970
RRA, Reinforced reduction aortoplasty; AAR, ascending aortic replacement; EF, ejec-
tion fraction.
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ters of sinuses were within the acceptable range, and no reop-
eration was required for all patients during the follow-up
period. In each group therewas no difference in the diameters
of the proximal aortic arch between the postoperative period
and late follow-up (RRA group: 28.7  0.8 vs 29.1  0.9
mm, P ¼ .06; AAR group: 29.1  1.3 vs 29.3  1.4 mm,
P ¼ .69). No late complications related to recurrent aortic
dilatation were identified during follow-up.DISCUSSION
Open surgical intervention is still the predominant thera-
peutic strategy for the treatment of ascending aortic aneu-
rysms in the era of endovascular intervention.12 According
to the various locations of the aorta impaired by pathological
changes, different surgical procedures are indicated. For an-
eurysms with aortic root involvement, root replacement orFIGURE 3. Mean diameter of aortic sinuses and proximal aortic arch of each gro
RRA, Reinforced reduction aortoplasty; AAR, ascending aortic replacement; pre
The Journal of Thoracic and Careconstruction is indicated. In terms of ascending aortic an-
eurysms without root involvement (ie, fusiform ascending
aortic aneurysm), AAR and RAA are frequently performed
procedures.1
RAA is generally considered conservative for the preser-
vation of the native aortic wall, whereas AAR is radical be-
cause of its surgical invasiveness.3,7 Along with progress
and refinement in surgical technique, the early surgical
results with both options have been significantly improved.2
However, RAAwithout external support was largely aban-
doned because of its demonstrated high recurrence rate of di-
latation.6 In recent years, a series of clinical studies have been
carried out focusing on the evaluation of RRA.13-16
Nevertheless, most of these results of RRA were reported
separately without comparison with the AAR procedure.
Therefore it would be less valuable to compare the early and
late outcomes with existing AAR data.
Another issue in previous studies of RRA is that the obser-
vation of postoperative redilatation was mostly focused
on the examination of the diameter of the ascending
aorta,2,13,16,17 whereas the fate of the aortic diameters at the
sinuses and distal aorta after RRA is left unknown.
In the latest decade, Egloff and associates4 reported that
RRA carried a lower complication rate than the other 3
procedures, including unsupported reduction aortoplasty,
supracoronary graft replacement, and composite graft re-
placement. Carrel and coworkers18 compared 3 different
surgical options for treatment of ascending aortic aneurysms
in a heterogeneous group of patients and reported a lowestup during follow-up. Numbers of patients at risk at each time point are given.
op, preoperatively; postop, postoperatively.
rdiovascular Surgery c Volume 141, Number 3 741
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in the reinforced RRA group over supracoronary graft
replacement and composite graft.
However, both studies were carried out in heterogeneous
cohorts because there were not only patients with ascending
aortic aneurysm with aortic root involved but also patients
without aortic roots involved. It is well known that ascend-
ing aortic aneurysms with or without roots involved indicate
different procedures and that the difference in the diseases
per se might lead to different outcomes. Therefore the
groups of patients in the 2 studies were not truly comparable,
which limited the reliability of the results and conclusion.
In addition, different cardiac procedures were often per-
formed in these studies, which might be an interference fac-
tor that affects the results significantly.13-16
Patients with ascending aortic aneurysms are most com-
monly combined with aortic valve disease.1,19 Polvani and
associates15 reported a high rate of 88.2% in their group.
We included all patients with fusiform ascending aorta and
AVR as the only concomitant procedure to maximize the
available cases and minimize the interference to the compar-
ison. For the evaluation of proximal and distal ascending
aortic diameters, we focused continuously on the diameters
of the aortic sinuses and proximal aortic arch, instead of the
ascending aorta, which was already demonstrated not likely
to be redilatated with 2 options.8,16
Like any decision making in modern cardiovascular sur-
gery, the value of every risk or benefit of the treatment should
be considered synthetically for patients with an ascending
aortic aneurysm. The factors that were well summarized by
Sievers20 include size, wall thickness, and pathology of the
aorta; hemodynamic load caused by aortic valve pathology;
concomitant cardiac surgery; and progression of dilatation.
Moreover, life expectancy and individual experience of the
surgeon also contribute to decision making.
Of these, the sizeof the ascending aorta and themorphology
of the aorticwall are usually considered themost important de-
terminants for the surgical intervention.16 Elefteriades21 sug-
gested that intervention for the ascending aortic aneurysm
should be indicated in adults with ascending aortic size of
greater than 55 mm for degenerative aneurysms. For patients
with BAV disease, surgical intervention should be considered
if the size is greater than 45 mm.22
According to Sievers,20 the threshold size is related to
body surface area, age, and pathology of the aortic wall.
However, all the abovementioned recommendations were
drawn from data of patients in the Western world, and it is
known that the body surface area of the normal adult is
smaller in Asian than in the Western world. Therefore we
hypothesize that a smaller threshold diameter would be
more appropriate in Asian patients. In our institute we
made the decision for surgical intervention when the diame-
ter of the ascending aorta reached 50 mm for degenerative
aneurysms and 40 mm for BAV disease.742 The Journal of Thoracic and Cardiovascular SurgTo the question of repair or replacement for a dilated
ascending aorta, Robicsek and associates1 pointed out that
patients with a diameter of greater than 6.0 cm should not
undergo reduction aortoplasty. However, we consider the
quality of the ascending aortic wall more than size as a deter-
minant for the choice because the oversized ascending aorta
could be reduced to normal range by aortoplasty if only the
quality (including thickness and pathology) of the aortic
wall is acceptable. In the current study the preoperative di-
ameter of the ascending aorta was not significantly predic-
tive of late death in the 2 groups according to the analysis
of risk factors related to late death.
Although there was no difference in terms of postopera-
tive events, shorter cardiopulmonary bypass time and aortic
crossclamp time and fewer red blood cells were used in pa-
tients undergoing RRA than in patients undergoing AAR,
reflecting the decreased technical complexity of the former
procedure. This will result in an improved preservation for
the myocardium and other organs, which can be advanta-
geous for patients with high operative risks and when con-
comitant procedures are required. This result indicates that
in this situation patients can benefit from RRA more than
from AAR.
According to recent studies, the perioperative mortality of
AAR and RRA was about 3%23,24 and 0% to 1.5%,2,15,17
respectively. There was no perioperative death in the
current cohort, and it should be attributed to the 3
following factors: relatively young patients, only AVR as
a concomitant procedure, and absence of aortic dissection
or Marfan syndrome in the present study.
Consistent with the previous studies,15-17 there was no
late redilatation of the ascending aorta after repair or
replacement during follow-up in the present study. More-
over, we further focused on monitoring of the diameters of
these 2 locations continuously. Our results show that both
procedures result in good late outcomes without significant
redilatation at the sinuses or proximal aortic arch. All diam-
eters measured by means of computed tomographic analysis
were within the acceptable range, and no reoperation was re-
quired, even in patients with BAV, which is defined as
a structural disorder of the aortic wall. We attribute this to
the decrease of tension in the aortic wall, which resulted
from the reduction in internal diameter caused by the opera-
tion, according to the law of LaPlace. This result suggests
that the fusiform ascending aorta with BAV is not a contrain-
dication for RRA or AAR.
Therefore we recommend that for the treatment of fusi-
form ascending aortic aneurysm, RRA should be more fre-
quently considered if only the quality of the aortic wall is
acceptable.
Study Limitations
There are 2 limitations in this comparative study, which
are the lack of prospective design and that the cases areery c March 2011
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existed as a result of the respective indications of the 2
procedures. Because of the relatively strict indication for
surgical procedures, a rigorous randomization in this kind
of study might compromise the patients and therefore be im-
practical to carry out. For this reason, we believe that the cur-
rent study is the most practical approach for comparison of
the 2 surgical options at the present time.
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